288 related articles for article (PubMed ID: 32871892)
21. Plum-blossom needle for coronavirus disease 2019-related headache: A protocol for systematic review and meta-analysis.
Gao W; Li J; Huang G
Medicine (Baltimore); 2020 Sep; 99(37):e22179. PubMed ID: 32925789
[TBL] [Abstract][Full Text] [Related]
22. The effect of diabetes on mortality of COVID-19: A protocol for systematic review and meta-analysis.
Yang Y; Zhong W; Tian Y; Xie C; Fu X; Zhou H
Medicine (Baltimore); 2020 Jul; 99(27):e20913. PubMed ID: 32629686
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials.
Meza N; Pérez-Bracchiglione J; Pérez I; Carvajal C; Ortiz-Muñoz L; Olguín P; Rada G; Madrid E;
Medwave; 2021 Mar; 21(2):e8105. PubMed ID: 33830976
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of Lianhua Qingwen (LHQW) for coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis.
Zhang Q; Cao F; Ji G; Xu X; Sun Y; Li J; Qi X; Sun S; Wang Y; Song B
Medicine (Baltimore); 2020 Jul; 99(30):e20979. PubMed ID: 32791675
[TBL] [Abstract][Full Text] [Related]
25. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis.
Zhang X; Cao D; Liu J; Zhang Q; Liu M
Medicine (Baltimore); 2020 Jul; 99(30):e21404. PubMed ID: 32791754
[TBL] [Abstract][Full Text] [Related]
27. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
28. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
29. Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension.
Gnanenthiran SR; Borghi C; Burger D; Charchar F; Poulter NR; Schlaich MP; Steckelings UM; Stergiou G; Tomaszewski M; Unger T; Wainford RD; Williams B; Rodgers A; Schutte AE
BMJ Open; 2021 Feb; 11(2):e043625. PubMed ID: 33593784
[TBL] [Abstract][Full Text] [Related]
30. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors.
Zhou X; Zhu J; Xu T
Clin Exp Hypertens; 2020 Oct; 42(7):656-660. PubMed ID: 32404011
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of depression during the SARS, MERS, and COVID-19 pandemics: A protocol for overview of systematic reviews.
Du L; Chen YM; Li Y; Yuan W; Wang JS
Medicine (Baltimore); 2020 Sep; 99(38):e22235. PubMed ID: 32957366
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the efficacy and safety of bromhexine hydrochloride tablets in treating pediatric COVID-19: A protocol for meta-analysis and systematic review.
Wang Y; Zhang Y; Chen X; Xue K; Zhang T; Ren X
Medicine (Baltimore); 2020 Sep; 99(37):e22114. PubMed ID: 32925756
[TBL] [Abstract][Full Text] [Related]
34. Traditional Chinese medicine for corona virus disease 2019: A protocol for systematic review.
Huang J; Wu L; Ren X; Wu X; Chen Y; Ran G; Huang A; Huang L; Zhong D
Medicine (Baltimore); 2020 Aug; 99(35):e21774. PubMed ID: 32871898
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of Chinese traditional medicine injections on patients with coronavirus disease 2019: A protocol for systematic review and meta analysis.
Li Y; Xu H; Lang H; Li J; Bi L; Li Y; Dong L; Zhang L; Liang X; Zhu H
Medicine (Baltimore); 2020 Jul; 99(31):e21024. PubMed ID: 32756089
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of Lianhua Qingwen in the treatment of patients with moderate COVID-19 infection: A protocol for systematic review and meta analysis.
Liu N; Zhang T; Ma L; Wang H; Cao Y; Yang Y; Pei H; Li H
Medicine (Baltimore); 2020 Aug; 99(33):e21614. PubMed ID: 32872017
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
Vaz de Castro PAS; Bitencourt L; Pereira BWS; Lima AQR; Hermida HS; Moreira Neto CR; Mestriner MD; Simões E Silva AC
Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
[TBL] [Abstract][Full Text] [Related]
38. A systematic review of etiology, epidemiology, clinical manifestations, image findings, and medication of 2019 Corona Virus Disease-19 in Wuhan, China.
Xu J; Ma XP; Bai L; Wang M; Deng W; Ning N
Medicine (Baltimore); 2020 Oct; 99(42):e22688. PubMed ID: 33080715
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of acupuncture and moxibustion in adjuvant treatment of patients with novel coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis.
Zhang Q; Xu X; Sun S; Cao F; Li J; Qi X; Ji G; Wang Y; Song B
Medicine (Baltimore); 2020 Jul; 99(28):e21039. PubMed ID: 32664113
[TBL] [Abstract][Full Text] [Related]
40. Chinese medicine for COVID-19: A protocol for systematic review and meta-analysis.
Chen H; Xie Z; Zhu Y; Chen Q; Xie C
Medicine (Baltimore); 2020 Jun; 99(25):e20660. PubMed ID: 32569196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
